Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Lung Neoplasms

Stage II-IIIB Non-small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Non Small Cell Lung Cancer Metastatic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Non Small Cell Lung Cancer Metastatic

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Lung Neoplasms

Clinical Trials

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

NEOLA

TARGET

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

CoC

A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain

Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer

SAVANNAH

A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positvie ctDNA After lead-in Osimertinib Monotherapy

BOOSTER

Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

MK-2870-003

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

ROSE

FLAME

AURA17

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study

NSCLC